Comparative in vitro evaluation of apheresis platelets stored with 100% plasma versus bicarbonated Ringer's solution with less than 5% plasma.
BACKGROUND
The major strategy for reducing the frequency of adverse reactions to platelet (PLT) transfusions is PLT washing with PLT additive solutions (PASs). In Japan, a mixture of medical infusion solutions such as acetate Ringer's solution, sodium bicarbonate, magnesium sulfate, and ACD-A is currently used as a PAS because none of the common types of PASs are officially permitted for clinical use. Recently, a bicarbonated Ringer's solution (BRS) was developed using bicarbonate as an alkaline agent. The aim of this study was to evaluate whether a BRS can effectively be utilized as a PAS for clinical use.


METHODS
The washing and storage solution was prepared by adding 25 mL ACD-A to 500 mL of BRS (BRS-A), consisting of 95.2 mmol/L NaCl, 3.8 mmol/L KCl, 0.9 mmol/L MgCl2 ,1.4 mmol/L CaCl2 , 26.6 mmol/L NaHCO3 , 5.8 mmol/L glucose, 4.2 mmol/L trisodium citrate, and 1.8 mmol/L citric acid. The in vitro properties of apheresis PLTs suspended in BRS-A with low concentration of plasma (<5%) were compared with those suspended in 100% plasma during 7-day storage.


RESULTS
The in vitro properties of pH, hypotonic shock response, glucose consumption rate, lactate production rate, swirling, CD62P, and CD42b expression in PLTs suspended in BRS-A were comparable or superior to those suspended in 100% plasma during 7-day storage.


CONCLUSIONS
BRS-A, prepared by mixing the only two solutions permitted for clinical use in Japan, has a positive capability to maintain PLT function. These results indicate that PLT washing and storage with BRS-A is feasible.
Japanese Red Cross Miyagi Blood Center, Sendai, Miyagi, Japan. s-oikawa@miyagi.bc.jrc.or.jp
Shinji
S
Oikawa
Dai
D
Sasaki
Masaki
M
Kikuchi
Yoshihiro
Y
Sawamura
Takashi
T
Itoh
D001792:Blood Platelets / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D001793:Blood Preservation / Q000379:methods; D002478:Cells, Cultured; D005240:Feasibility Studies; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007552:Isotonic Solutions / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D019344:Lactic Acid / Q000378:metabolism; D009994:Osmolar Concentration; D010949:Plasma / Q000737:chemistry / Q000502:physiology*; D017713:Platelet Transfusion; D010983:Plateletpheresis; D012996:Solutions / Q000737:chemistry / Q000494:pharmacology
D007552:Isotonic Solutions; D012996:Solutions; C506920:bicarbonated Ringer's solution; D019344:Lactic Acid; D005947:Glucose